TY - JOUR T1 - Enrichment of <em>SARM1</em> alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disorders JF - medRxiv DO - 10.1101/2021.06.17.21258268 SP - 2021.06.17.21258268 AU - Jonathan Gilley AU - Oscar Jackson AU - Menelaos Pipis AU - Mehrdad A. Estiar AU - Ammar Al-Chalabi AU - Matt C. Danzi AU - Kristel R. van Eijk AU - Stephen A. Goutman AU - Matthew B. Harms AU - Henry Houlden AU - Alfredo Iacoangeli AU - Julia Kaye AU - Leandro Lima AU - Queen Square Genomics AU - John Ravits AU - Guy A. Rouleau AU - Rebecca Schüle AU - Jishu Xu AU - Stephan Züchner AU - Johnathan Cooper-Knock AU - Ziv Gan-Or AU - Mary M. Reilly AU - Michael P. Coleman Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/11/12/2021.06.17.21258268.abstract N2 - SARM1, a protein with critical NADase activity, is a central executioner in a conserved programme of axon degeneration. We report seven rare missense or in-frame microdeletion human SARM1 variant alleles in patients with amyotrophic lateral sclerosis (ALS) or other motor nerve disorders that alter the SARM1 auto-inhibitory ARM domain and constitutively hyperactivate SARM1 NADase activity. The constitutive NADase activity of these seven variants is similar to that of SARM1 lacking the entire ARM domain and greatly exceeds the activity of wild-type SARM1, even in the presence of nicotinamide mononucleotide (NMN), its physiological activator. This rise in constitutive activity alone is enough to promote neuronal degeneration in response to otherwise non-harmful, mild stress. Importantly, these strong gain-of-function alleles are completely patient-specific in the cohorts studied and show a highly significant association with disease at the single gene level. These findings of disease-associated coding variants that alter SARM1 function build on previously reported genome-wide significant association with ALS for a neighbouring, more common SARM1 intragenic single nucleotide polymorphism (SNP) to support a contributory role of SARM1 in these disorders. A broad phenotypic heterogeneity and variable age-of-onset of disease among patients with these alleles also raises intriguing questions about the pathogenic mechanism of hyperactive SARM1 variants.Competing Interest StatementFunding of academic projects from AstraZeneca and Michael Coleman is a consultant for Nura Bio.Funding StatementThis work was supported by a grant from the Robert Packard Center for ALS Research at Johns Hopkins (to M.P.C, also supporting J.G.) and in part by data provided by the Answer ALS Consortium, also administered by the Robert Packard Center. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of The Johns Hopkins University or any grantor proving funds to its Robert Packard Center for ALS Research. Parts of this work were also supported by UK Biotechnology and Biological Sciences Research Council (BBSRC) / AstraZeneca Industrial Partnership award BB/S009582/1 (to M.P.C, also supporting J.G., O.J.) and Wellcome Trust Collaborative award 220906/Z/20/Z (to M.P.C and M.M.R, also supporting J.G., O.J., M.P.). Additional support was provided by UK Medical Research Council (MRC) awards MR/L501529/1 and MR/R024804/1 and the UK Economic and Social Research Council (ESRC) award ES/L008238/1 under the aegis of the EU Joint Programme, Neurodegenerative Disease Research (JPND) (www.jpnd.eu) (to A.A-C.), the Motor Neurone Disease (MND) Association and the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London (A.A-C., A.I.), National Institute of Neurological Diseases and Stroke (NINDS) and office of Rare Diseases awards U54NS065712 (to M.M.R., also supporting M.P.), and 5R01NS072248-10 and 5R01NS105755-03 (to S.Z., also supporting M.C.D.), National Institute of Environmental Health Sciences (NIEHS) award K23ES027221 (to S.A.G.), and Wellcome Trust award 216596/Z/19/Z (to J.C.K.). Samples used in this research were in part obtained from the UK National DNA Bank for MND Research, funded by the MND Association and the Wellcome Trust. Sample management was undertaken by Biobanking Solutions funded by the MRC at the Centre for Integrated Genomic Medical Research, University of Manchester. Whole-genome sequencing of the Lothian Birth Cohorts was funded by the Biotechnology and Biological Sciences Research Council.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a retrospective study using anonymised data so specific consent was not obtained by the authors, but consent was obtained at each site that contributed patient information to this study in accordance with their local Institutional Review Boards (IRBs). Patient information for the Answer ALS project dataset was already publicly available at the initiation of this study. Non-public datasets were covered by the following IRBs: the Comité de ética de la Investigación del Hospital Carlos III, Madrid, Spain; the University Medical Center Utrecht Medical Ethics Committee, Utrecht, The Netherlands; the Committee for the Protection of Human Subjects in Research of the University of Massachusetts Medical School, Worcester, MA, USA; and the Trent University Medical Ethics Committee, UK for Project MinE patients; the Benaroya Research Institute IRB, Seattle, WA, USA; the University of California San Diego IRB, San Diego, CA, USA; and the University of Miami IRB committee (20070282 / MODCR00002569), Miami, FL, USA for GENESIS patients; the London - Queen Square Research Ethics Committee (study. no. 09/H0716/61), UK for the UCL cohort patient; and the University of Michigan IRB (HUM00116765), Ann Arbor, MI, USA for the unattributed patient. Non-public datasets can be obtained on request.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data is presented in the manuscript and/or links or citations are provided to the databases used. Project MinE data freeze 1 allele frequency data and clinical datasets for Answer ALS patients presented in this study are freely searchable/available (see links below). If additional information relating to other allele frequencies and/or clinical data is required then the corresponding authors would be able to facilitate contact with the appropriate database managers and/or clinicians. http://databrowser.projectmine.com/ https://dataportal.answerals.org/home ER -